Semaglutide + Ipamorelin Blend
How this combination works
The community rationale is to pair a GLP-1 agonist that drives fat loss through reduced appetite and intake with a growth hormone secretagogue intended to help preserve lean mass during the caloric deficit. Semaglutide's weight-loss effect rests on human RCT evidence (see its peptide page), while ipamorelin's GH-releasing selectivity comes from animal and human pharmacokinetic studies. The lean-mass-preservation premise for this pair is mechanistic inference, not a tested outcome. Two findings in ipamorelin's file point the other way: GH-independent increases in body fat and food intake in mice, and GHS-class reports of appetite changes and dysglycaemia — both of which run against semaglutide's intended effect.
Combined mechanism
Semaglutide binds and activates the GLP-1 receptor. Proposed mechanisms include reduced appetite and increased satiety, improved insulin sensitivity, reduced de novo lipogenesis and reduced adipose tissue weight. Ipamorelin is a selective agonist at the ghrelin receptor (GHS-R1a) that stimulates GH release from the anterior pituitary without significantly elevating ACTH or cortisol at doses far above its GH-releasing ED50 in swine. In healthy men it produced dose-proportional kinetics, a terminal half-life of about 2 hours and a single GH peak at roughly 0.67 hours. It also stimulates insulin secretion in vitro. The two act on different receptors (GLP-1R vs GHS-R1a). Ghrelin-receptor agonism is classically orexigenic, and ipamorelin increased food intake in mice, so the two may partly work against each other on appetite. No human pharmacokinetic or pharmacodynamic data exist for the combination.
What each component does
Evidence base for this combination
Safety considerations for this combination
- No combination-specific safety data exist for Semaglutide + Ipamorelin. The signals below come from each compound studied on its own. Component approved files
- Opposing appetite signals: ipamorelin increased food intake and body fat in mice (including GH-intact animals), the opposite of semaglutide's intended effect. Whether this matters at community doses in humans is unstudied. Ipamorelin: PMID: 11162489
- Both compounds affect glucose handling — semaglutide through GLP-1R signalling and ipamorelin through insulin-secretion and GH-axis effects (dysglycaemia is a reported GHS-class adverse effect). Combined glycaemic effects have not been studied. PMID: 40538007 (semaglutide); PMID: 15665799, 42395176 (ipamorelin)
- In the Phase II RCT (n=114), any treatment-emergent adverse events occurred in 87.5% of the ipamorelin group vs 94.8% of the placebo group; specific adverse events not detailed in abstract beyond nausea and vomiting endpoints. No significant safety differences from placebo were highlighted. Inherited from Ipamorelin (PMID: 25331030)
- GH-independent increase in body fat (adiposity), increased food intake, and elevated serum leptin observed in mice treated with ipamorelin (s.c., twice daily), including in GH-intact animals. Inherited from Ipamorelin (PMID: 11162489)
- Ipamorelin stimulates insulin secretion from pancreatic tissue of normal and diabetic rats in vitro, suggesting potential for glycemic effects. Inherited from Ipamorelin (PMID: 15665799)
- Class-wide adverse effects reported for GHS/ipamorelin in self-administration literature include endocrine and metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions. Inherited from Ipamorelin (PMID: 42395176)
- Semaglutide's approved file lists no compound-specific safety signals. That reflects limited study, not established safety; see the Semaglutide peptide page. Semaglutide approved file
Contraindications
- Semaglutide is a prescription drug (Ozempic, Wegovy, Rybelsus); ipamorelin is not approved for any indication. Adding an unapproved GH secretagogue to a prescribed GLP-1 regimen has not been evaluated in any trial. Semaglutide and ipamorelin regulatory status per their approved files
- No specific contraindications are explicitly stated in the reviewed abstracts for ipamorelin. Use in patients with diabetes mellitus may produce unpredictable GH hypersecretion responses (demonstrated in streptozotocin-diabetic mice). Inherited from Ipamorelin (PMID: 14630569)
- Use by competitive athletes is contraindicated under WADA rules, as ipamorelin is listed on the WADA Prohibited List. Inherited from Ipamorelin (PMID: 26578461)
- Semaglutide + Ipamorelin has not been evaluated as a combination in any clinical trial. The lack of combination-specific contraindications reflects that absence of study, not established safety. No combination study cited in either component file